Holifya Raises €2M for AI Obesity Care Expansion

Holifya, an Italian digital health innovator, has successfully closed a €2 million funding round to accelerate its AI-powered approach to obesity management. The investment, comprising €1.6 million in equity and €0.4 million in debt and grants, signals strong confidence in the company's unique model for personalized pharmacologic treatment. This capital infusion is earmarked for enhancing its proprietary artificial intelligence capabilities, expanding its B2C reach across Italy through strategic partnerships, and bolstering its clinical team.

The funding was spearheaded by Next Age, the Silver Economy program of CDP Venture Capital's National Accelerator Network, alongside significant contributions from AC75, Growth Engine (a returning investor), Doorway, 20Fund with its GP Serra Elizabeth Falk, and Zooga VC. The investor roster also features prominent angel investors, underscoring the broad appeal of Holifya's mission.

Holifya distinguishes itself by integrating advanced diagnostics, a sophisticated AI engine, and a multidisciplinary clinical care framework. Its AI system analyzes an extensive array of patient data, potentially up to 3,000 biomarkers including genetic and blood chemistry profiles, alongside behavioral and clinical information. This comprehensive data set allows for highly personalized treatment plans, particularly for therapies like GLP-1/GIP drugs, which are revolutionizing obesity treatment but often suffer from adherence issues and side effects.

The market context for Holifya's solution is substantial. Italy officially recognized obesity as a chronic, progressive, and relapsing disease in 2025, with over 23 million adults classified as overweight or obese. Critically, approximately 11 million of these individuals are candidates for GLP-1 therapy, representing one of Europe's largest potential patient pools. However, current treatment penetration remains low, with less than 1% of eligible patients receiving therapy, highlighting a significant unmet need.

A key challenge Holifya addresses is patient retention. The company reports that its AI-driven personalization leads to weight loss outcomes up to twice as effective as standard drug administration (-17% vs. -7.1% at 6 months) and adherence rates triple the market average. This is achieved by proactively identifying and mitigating potential side effects and optimizing dosage, thereby reducing patient dropout rates, which exceed 30% within the first month and over 50% within a year for conventional treatments.

Holifya's technology also streamlines patient access. Eligibility screening is completed within 48 hours, a stark contrast to the months-long waiting periods often experienced within the Italian National Health Service. The AI system continuously monitors patient progress, flagging dropout risks and potential adverse events to treating physicians, who then validate and implement the most effective therapeutic adjustments. Each patient interaction further refines the AI's predictive accuracy, creating a virtuous cycle of improved care.

This funding round positions Holifya to solidify its first-mover advantage in building the essential clinical and technological infrastructure for advanced GLP-1/GIP care in Italy. By leveraging AI and data-driven insights, the company aims to significantly improve patient outcomes and address the growing public health challenge of obesity.